ALK fusions are seen in 3–5% of NSCLC patients and are more common among the following groups: no prior smoking history, adenocarcinoma histology, younger age, female gender, and tumors with wild type EGFR and KRAS (16, 19–21). The gene discussed is KRAS; the disease is non-small cell lung carcinoma.